Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Significant Accounting Policies - Schedule of Major Customer Data as a Percentage of Total Revenues (Details)

v3.25.1
Significant Accounting Policies - Schedule of Major Customer Data as a Percentage of Total Revenues (Details) - Customer Concentration Risk [Member] - Revenue Benchmark [Member]
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Schedule of Major Customer Data as a Percentage of Total Revenues [Line Items]      
Percentage of total revenues 100.00% 100.00% 100.00%
Cipher Pharmaceuticals (Canada) [Member]      
Schedule of Major Customer Data as a Percentage of Total Revenues [Line Items]      
Percentage of total revenues 7.00% 11.00% 11.00%
Chong Kun Dang Pharmaceuticals Corp. (South Korea) [Member]      
Schedule of Major Customer Data as a Percentage of Total Revenues [Line Items]      
Percentage of total revenues 11.00% 25.00% 25.00%
Gebro Holding GmbH (Austria) [Member]      
Schedule of Major Customer Data as a Percentage of Total Revenues [Line Items]      
Percentage of total revenues 11.00% 18.00% 18.00%
Ewopharma AG (Switzerland) [Member]      
Schedule of Major Customer Data as a Percentage of Total Revenues [Line Items]      
Percentage of total revenues 30.00% 46.00% 46.00%
Vetbiolix (France) [Member]      
Schedule of Major Customer Data as a Percentage of Total Revenues [Line Items]      
Percentage of total revenues 41.00%